Neogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025. In the quarter to August 2026, revenue grew 6.51%, EPS fell 132.1%, free cash flow grew 135.8% and total debt fell 2.31%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow NEOG
Neogen Corporation (NEOG) EV/Sales
As of 16 October 2026, Neogen Corporation (NEOG) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from 1.5× (October 2022) to 11.8× (September 2018); the current reading is higher than 16% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 2.9× | 32.01% |
| FY2025 | 2.2× | (42.10%) |
| FY2024 | 3.9× | (19.57%) |
| FY2023 | 4.8× | 2.44% |
| FY2022 | 4.7× | (51.01%) |
| FY2021 | 9.6× | 16.47% |
| FY2020 | 8.2× | 27.97% |
| FY2019 | 6.4× | (30.60%) |
| FY2018 | 9.2× | 46.78% |
| FY2017 | 6.3× | 16.32% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Aug 2026 | 3.6× | 20.52% |
| May 2026 | 2.9× | (16.62%) |
| Feb 2026 | 3.5× | 59.41% |
| Nov 2025 | 2.2× | 3.71% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INSP Inspire Medical Systems, Inc. compare | 1.9× |
| ATEC Alphatec Holdings, Inc. compare | 2.6× |
| NEOG Neogen Corporation | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.2× |
| IRTC iRhythm Holdings, Inc. compare | 4.4× |
| AXGN AxoGen, Inc. compare | 7.0× |
| ESTA Establishment Labs Holdings Inc. compare | 8.1× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)